



Gerstner Sloan Kettering
Graduate School of Biomedical Sciences

[Welcome to GSK](#)

MEMORIAL HOSPITAL RESEARCH LABORATORIES

[Admissions](#)

The Kenneth Offit Lab

[Cancer Biology](#)

Faculty

[Cancer Engineering](#)

Research

[Research](#)

[Alumni](#)



Kenneth Offit, MD

Professor

Research in the laboratory focuses on the discovery and characterization of novel cancer predisposing genes in humans, including both common and rare variants. We conduct studies to describe phenotype, penetrance, modifying effect, and clinical outcomes associated with germline genetic alterations in cancer patients and their families. In addition, our research focuses on the interpretation and clinical translation of

results of massively parallel sequencing of germline genomes in cancer-prone kindreds.

[View Lab Overview](#) →



Featured News



[Meet the 2021-2022 Andrew Sabin Family Foundation Fellows](#)

FINDING



[Repairing DNA Damage in Cancer Cells](#)

New findings could lead to a different kind of cancer drug that targets a DNA damage repair pathway called nucleotide excision repair.

IN THE CLINIC



[Innovative Research Center Will Explore Hereditary Cancer Genes](#)

MSK's new Robert and Kate Niehaus Center for Inherited Cancer Genomics is using the latest in gene sequencing technologies to discover the inherited causes of cancer.

[View All Featured News](#)

Publications

[Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchiotti L, Lipkin SM. Germline Lysine-Specific Demethylase 1 \(*LSD1/KDM1A*\) Mutations Confer Susceptibility to Multiple Myeloma. *Cancer Res.* 2018 May 15;78\(10\):2747-2759.](#)

[Katona BW, Yurgelun MB, Garber JE, Offit K, Domchek SM, Robson ME, Stadler ZK. A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. *Genet Med.* 2018 Mar 1.](#)

[Walsh MF, Kennedy J, Harlan M, Kentsis A, Shukla N, Musinsky J, Roberts S, Kung AL, Robson M, Kushner BH, Meyers P, Offit K. Germline *BRCA2* mutations detected in pediatric sequencing studies impact parents' evaluation and care. *Cold Spring Harb Mol Case Stud*. 2017 Nov 21;3\(6\).](#)

[Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, Lipkin SM, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA*. 2017 Sep 5;318\(9\):825-835. Doi: 10.1001/jama.2017.11137](#)

[Hamilton JG, Shuk E, Genoff MC, Rodríguez VM, Hay JL, Offit K, Robson ME. Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. *J Oncol Pract*. 2017 Jul;13\(7\):e590-e601.](#)

[View All Publications](#)

People



Kenneth Offit, MD

Professor

Cancer geneticist Kenneth Offit focuses on gene characterization; genetic and epidemiologic studies of cancer-predisposing alleles; and the therapeutic, prognostic, and psychosocial translation of these findings.

MD, Harvard Medical School

✉ offitk@mskcc.org

Email Address


☎ [646-888-4059](tel:646-888-4059)

Office Phone

👤 [View physician profile](#)

Physician profile

Members




Kenneth
Offit
Lab Head



Zsafia K. Stadler
Lead, Inherited
Gastrointestinal Cancer
Genomics, Niehaus Center

Vijai
Joseph
Associate Attending
Geneticist; Director of
Bioinformatics, Niehaus
Center




Sami Belhadj
Research Fellow

Mark E.
Robson
Chief, Breast Medicine
Service; Lead, Inherited
Breast Cancer Genomics,
Niehaus Center

Maria Carlo
Lead, Inherited
Genitourinary Cancer
Genomics, Niehaus Center

Sita Dandiker

Bryan Devolder



Yelena
Kemel
Niehaus Center Program
Manager



Ying Liu

Lead, Inherited
Gynecological Cancer
Genomics, Niehaus Center



Semanti
Mukherjee

Associate Attending
Geneticist; Director of
Bioinformatics, Niehaus
Center



Vignesh
Ravichandran

Bioinformatics Specialist



Kaitlyn Tkachuk



Sabine Topka

Associate Director of
Laboratory Operations;
Head, Functional
Genomics, Niehaus Center



Michael Walsh

Lead, Inherited Pediatric
Cancer Genomics,
Niehaus Center

Lab Alumni
+

Lab Affiliations
+

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

Bioinformatics Specialist

[Apply now](#) →

Career Opportunities

[Apply now](#) →

Computational Genetics Fellow

[Apply now](#) →

[View All Open Positions](#)

Get in Touch

✉ offitk@mskcc.org
Lab Head Email

☎ [646-888-4059](tel:646-888-4059)
Office Phone

☎ [646-888-4081](tel:646-888-4081)

Office Fax

 [646-888-3098](tel:646-888-3098)

Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Kenneth Offit discloses the following relationships and financial interests:

AnaNeo Therapeutics

Equity

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies [here](#). For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility Statement](#)

[Privacy policy](#)

[Public notices](#)

© 2024 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center